Oct 14 (Reuters) - The World Health Organization said on Monday it had approved Bavarian Nordic's (BAVA.CO), opens new tab mpox vaccine for adolescents aged 12 to 17 years, an age group considered ...

LONDON, Sept 19 (Reuters) - Bavarian Nordic (BAVA.CO), opens new tab said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using ...

Bavarian Nordic’s Mpox vaccine met with the World Health ... decision comes after the European Union (EU) approved the drug for vaccinating adolescents in September. The Danish biotech major ...

The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The European Union’s drug regulator has approved Bavarian Nordic's mpox vaccine for use in adolescents aged 12 to 17, expanding its availability amid the ongoing outbreak in parts of Africa.

The European Commission (EC) has extended the marketing authorisation for Bavarian Nordic’s smallpox and mpox vaccine to include adolescents aged 12 to 17 years. Imvanex (MVA-BN) is already approved ...